Arovella Therapeutics Ltd - Asset Resilience Ratio
Arovella Therapeutics Ltd (ALA) has an Asset Resilience Ratio of 95.65% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Arovella Therapeutics Ltd debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2025)
This chart shows how Arovella Therapeutics Ltd's Asset Resilience Ratio has changed over time. See ALA total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Arovella Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ALA stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$19.37 Million | 95.65% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$19.37 Million | 95.65% |
Asset Resilience Insights
- Very High Liquidity: Arovella Therapeutics Ltd maintains exceptional liquid asset reserves at 95.65% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Arovella Therapeutics Ltd Industry Peers by Asset Resilience Ratio
Compare Arovella Therapeutics Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Arovella Therapeutics Ltd (2006–2025)
The table below shows the annual Asset Resilience Ratio data for Arovella Therapeutics Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 96.65% | AU$20.88 Million ≈ $14.77 Million |
AU$21.60 Million ≈ $15.28 Million |
+0.95pp |
| 2024-06-30 | 95.71% | AU$12.71 Million ≈ $9.00 Million |
AU$13.28 Million ≈ $9.40 Million |
+1.11pp |
| 2023-06-30 | 94.60% | AU$5.18 Million ≈ $3.66 Million |
AU$5.47 Million ≈ $3.87 Million |
+28.70pp |
| 2022-06-30 | 65.90% | AU$6.07 Million ≈ $4.30 Million |
AU$9.21 Million ≈ $6.52 Million |
+3.05pp |
| 2021-06-30 | 62.85% | AU$6.72 Million ≈ $4.75 Million |
AU$10.69 Million ≈ $7.56 Million |
+48.28pp |
| 2020-06-30 | 14.57% | AU$977.47K ≈ $691.62K |
AU$6.71 Million ≈ $4.75 Million |
-11.97pp |
| 2019-06-30 | 26.54% | AU$4.31 Million ≈ $3.05 Million |
AU$16.25 Million ≈ $11.50 Million |
+25.95pp |
| 2018-06-30 | 0.59% | AU$98.13K ≈ $69.43K |
AU$16.64 Million ≈ $11.78 Million |
-8.25pp |
| 2017-06-30 | 8.84% | AU$1.77 Million ≈ $1.25 Million |
AU$20.02 Million ≈ $14.16 Million |
+8.13pp |
| 2009-06-30 | 0.71% | AU$118.52K ≈ $83.86K |
AU$16.61 Million ≈ $11.75 Million |
-0.01pp |
| 2008-06-30 | 0.73% | AU$116.62K ≈ $82.52K |
AU$16.06 Million ≈ $11.37 Million |
-8.25pp |
| 2007-06-30 | 8.98% | AU$1.89 Million ≈ $1.33 Million |
AU$21.00 Million ≈ $14.86 Million |
+1.64pp |
| 2006-06-30 | 7.34% | AU$1.22 Million ≈ $863.57K |
AU$16.63 Million ≈ $11.77 Million |
-- |
About Arovella Therapeutics Ltd
Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, … Read more